“Zamboni announces new results of the Brave Dreams study
The professor continues the analysis on Ccsvi: "New important evidences will be published shortly"
The Ferrara professor Paolo Zamboni, director of the Translational Medicine and Surgery section of the University of Ferrara and principal investigator of Brave Dreams, was a guest at the scientific meeting held in San Vito di Cadore (Belluno), at the conclusion of the event Vertical Solid 2018 organized by the Il Bene Foundation, which deals with research on rare and neuroimmune diseases in collaboration with the Irccs Neurological Sciences of Bologna.
The appointment - expected by many patients and family members who have always followed the scientific research and dissemination activities of the Foundation - has been partly dedicated to Ccsvi (Chronic Cerebrospinal venous insufficiency) and to the clinical study financed by the Emilia Romagna Region to purpose of analyzing the efficacy and safety of balloon angioplasty (PTA) in the main extracranial veins as innovative therapy of multiple sclerosis (Sm).
In the second session of the conference - under the moderation of the neurologist Fabrizio Salvi, head of the Il Bene Center - Professor Zamboni spoke on the topic "New data from Brave Dreams" underlining how the press has only partially reported the evidence that emerged from scientific experimentation .
The sub-study of the study, which could enroll only 130 patients compared to the approximately 600 expected and the limited effectiveness of the technique of dilated angioplasty (PTA) that only in about half of the treated patients could ensure a satisfactory venous flow of the jugular veins - since just over 50% of patients have a Ccsvi that can be corrected with balloon angioplasty - the results have been severely conditioning.
Zamboni therefore anticipated that "important new evidences will be published shortly by elaborating other data from the Brave Dreams study". The professor from Ferrara also praised the work done by Dr. Salvi who, in his own center, enrolled almost half of the patients in the study entirely financed by the Emilia Romagna Region. By allowing, in fact, this important scientific trial supported by this considerable public funding to come to an end, with valuable results for science and for the patients of Ccsvi and Sm.”

Translated by Google translate:

https://www.estense.com/?p=709124